Related Experiment Video
Updated: Jan 2, 2026
Primary Microglia Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue
Published on: August 15, 2012
Pharmacological Targeting of Microglial Activation: New Therapeutic Approach
Cai-Yun Liu1, Xu Wang1, Chang Liu1
1Department of Neurology, The First Hospital of Jilin University, Changchun, China.
Abstract:
Mounting evidence suggests that neuroinflammation is not just a consequence but a vital contributor to the development and progression of Parkinson's disease (PD). Microglia in particular, may contribute to the induction and modulation of inflammation in PD. Upon stimulation, microglia convert into activated phenotypes, which exist along a dynamic continuum and bear different immune properties depending on the disease stage and severity. Activated microglia release various factors involved in neuroinflammation, such as cytokines, chemokines, growth factors, reactive oxygen species (ROS), reactive nitrogen species (RNS), and prostaglandins (PGs). Further, activated microglia interact with other cell types (e.g., neurons, astrocytes and mast cells) and are closely associated with α-synuclein (α-syn) pathophysiology and iron homeostasis disturbance. Taken together, microglial activation and microglia-mediated inflammatory responses play essential roles in the pathogenesis of PD and elucidation of the complexity and imbalance of microglial activation may shed light on novel therapeutic approaches for PD.
Insights
Microglia-driven neuroinflammation is a key factor in Parkinson's disease (PD) development. Understanding microglial activation is crucial for developing new PD treatments.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Neuroinflammation is increasingly recognized as a critical factor in Parkinson's disease (PD) pathogenesis.
- Microglia, the resident immune cells of the brain, play a central role in modulating inflammatory responses in PD.
Purpose of the Study:
- To explore the multifaceted role of microglial activation in Parkinson's disease.
- To elucidate how microglial phenotypes and their secreted factors contribute to PD progression.
Main Methods:
- Review of current literature on microglial biology in the context of PD.
- Analysis of the dynamic continuum of microglial activation states.
- Examination of interactions between activated microglia and other cellular components in PD.
Main Results:
- Activated microglia release pro-inflammatory mediators including cytokines, chemokines, ROS, RNS, and PGs.
- Microglial activation is closely linked to alpha-synuclein pathology and disruptions in iron homeostasis.
- Microglia interact with neurons, astrocytes, and mast cells, influencing the overall inflammatory milieu.
Conclusions:
- Microglial activation and associated inflammatory responses are integral to Parkinson's disease pathogenesis.
- The complexity and dysregulation of microglial activation present potential therapeutic targets for PD.
- Further research into microglial dynamics may reveal novel strategies for treating Parkinson's disease.
